Last reviewed · How we verify
Nix Creme Rinse Lice Treatment
Nix Creme Rinse Lice Treatment, marketed by Alliance Pharmaceuticals, is an established product in the lice treatment market. A key strength is the protection afforded by its composition patent, which is set to expire in 2028. The primary risk is the potential increase in competition following the patent expiry.
At a glance
| Generic name | Nix Creme Rinse Lice Treatment |
|---|---|
| Sponsor | Alliance Pharmaceuticals |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate the Efficacy and Safety of a Leave-in Spray in Subjects With Head Lice Infestation (PHASE4)
- Cocamide DEA vs Permethrin for Head Lice (PHASE3)
- A Safety and Efficacy Pilot Study Comparing NatrOVA Creme Rinse 1% and NIX Creme Rinse (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nix Creme Rinse Lice Treatment CI brief — competitive landscape report
- Nix Creme Rinse Lice Treatment updates RSS · CI watch RSS
- Alliance Pharmaceuticals portfolio CI